Dude
Senior Member
- Messages
- 227
MONTREAL--(BUSINESS WIRE)--Laurent Pharmaceuticals Inc., a Montreal-based biopharmaceutical company, today announced that it has obtained the approval from Health Canada to initiate ESSOR, an adaptive Phase 2/3 randomized placebo-controlled trial testing its oral drug candidate LAU-7b as a potential treatment for Long COVID.
About LAU-7b
LAU-7b is developed as a host-directed oral once-a-day COVID-19 therapeutic targeting host cells membrane lipids to exert dual antiviral and inflammation-controlling activities. SARS-CoV-2 must reprogram host cellular lipid metabolism to favor its entry and replication, a mechanism shared by all lipid-enveloped viruses. Fenretinide, the active ingredient in LAU-7b, works by modulating host cell membrane lipids and de-novo cell lipogenesis needed for virus replication. Because it acts on the host rather than the virus, LAU-7b has potential for broad-spectrum antiviral activity regardless of mutations, as already demonstrated in-vitro on multiple coronavirus variants. Fenretinide was also shown to trigger certain membrane phospholipids metabolic pathways involved in the resolution phase of inflammation, a natural mechanism that keeps the inflammatory response under control without inducing immune-suppression.
https://www.businesswire.com/news/h...aurent-Pharmaceuticals-Receives-Health-Canada
About LAU-7b
LAU-7b is developed as a host-directed oral once-a-day COVID-19 therapeutic targeting host cells membrane lipids to exert dual antiviral and inflammation-controlling activities. SARS-CoV-2 must reprogram host cellular lipid metabolism to favor its entry and replication, a mechanism shared by all lipid-enveloped viruses. Fenretinide, the active ingredient in LAU-7b, works by modulating host cell membrane lipids and de-novo cell lipogenesis needed for virus replication. Because it acts on the host rather than the virus, LAU-7b has potential for broad-spectrum antiviral activity regardless of mutations, as already demonstrated in-vitro on multiple coronavirus variants. Fenretinide was also shown to trigger certain membrane phospholipids metabolic pathways involved in the resolution phase of inflammation, a natural mechanism that keeps the inflammatory response under control without inducing immune-suppression.
https://www.businesswire.com/news/h...aurent-Pharmaceuticals-Receives-Health-Canada
Last edited:
